Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis

Kidney and Blood Pressure Research

Volumn 41, Issue 6, 2016, Pages 997-1007

  Worawichawong, Supanat ^a   Worawichawong, Suchin ^a   Radinahamed, Piyanuch ^a   Muntham, Dittapol ^b   Sathirapongsasuti, Nuankanya ^a   Nongnuch, Arkom ^a   Assanatham, Montira ^a   Kitiyakara, Chagriya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Rajamangala University of Technology Suvarnabhumi   (Thailand)

Author keywords

Biomarker; Chronic kidney disease; EGF; Epidermal Growth Factor; Fibrosis; Glomerulonephritis; Kidney; MCP 1; Monocyte chemoattractant protein 1; Neutrophil gelatinase associated lipocalin; NGAL; Tubulointerstitial

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; PREDICTIVE VALUE; PRIMARY GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TUBULAR ATROPHY AND INTERSTITIAL FIBROSIS; URINALYSIS; ATROPHY; FIBROSIS; KIDNEY TUBULE; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; URINE;

ADULT; ATROPHY; BIOMARKERS; CHEMOKINE CCL2; EPIDERMAL GROWTH FACTOR; FEMALE; FIBROSIS; GLOMERULONEPHRITIS; HUMANS; KIDNEY TUBULES; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 85008627353     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000452595     Document Type: Article

References (35)

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-272.
2. Floege J, Amann K: Primary glomerulonephritides. Lancet 2016;387:2036-2048.
3. Satirapoj B, Nast CC, Adler SG: Novel insights into the relationship between glomerular pathology and progressive kidney disease. Adv Chronic Kidney Dis 2012;19:93-100.
4. Cravedi P, Remuzzi G: Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 2013;76:516-523.
5. Hodgkins KS, Schnaper HW: Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol 2012;27:901-909.
6. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;52:595-605.
7. Ding H, He Y, Li K, Yang J, Li X, Lu R, Gao W: Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007;123:227-234.
8. Nickolas TL, Forster CS, Sise ME, Barasch N, Valle DS, Viltard M, Buchen C, Kupferman S, Carnevali ML, Bennett M, Mattei S, Bovino A, Argentiero L, Magnano A, Devarajan P, Mori K, Erdjument-Bromage H, Tempst P, Allegri L, Barasch J: NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int 2012;82:718-722.
9. Haller H, Bertram A, Nadrowitz F, Menne J: Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens 2016;25:42-49.
10. Kim MJ, Tam FW: Urinary monocyte chemoattractant protein-1 in renal disease. Clin Chim Acta 2011;412:2022-2030.
11. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP: Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 1996;7:906-913.
12. Lucarelli G, Mancini V, Galleggiante V, Rutigliano M, Vavallo A, Battaglia M, Ditonno P: Emerging urinary markers of renal injury in obstructive nephropathy. Biomed Res Int 2014;2014:303298.
13. Gesualdo L, Di Paolo S, Calabro A, Milani S, Maiorano E, Ranieri E, Pannarale G, Schena FP: Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int 1996;49:656-665.
14. Stangou M, Alexopoulos E, Papagianni A, Pantzaki A, Bantis C, Dovas S, Economidou D, Leontsini M, Memmos D: Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton) 2009;14:613-620.
15. Torres DD, Rossini M, Manno C, Mattace-Raso F, D'Altri C, Ranieri E, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP: The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 2008;73:327-333.
16. National High Blood Pressure Education P: In: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD), National Heart, Lung, and Blood Institute (US), 2004.
17. Kidney Disease: Improving Global Outcomes (KDiGO) Glomerulonephritis Work Group. KDiGO 2012 Clinical Practice Guideline for Glomerulonephritis. Kidney Inter Suppl 2012;2:139-274.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
19. Kidney Disease: Improving Global Outcomes (KDiGO) CKD Work Group. KDiGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
20. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
21. Youden WJ: Index for rating diagnostic tests. Cancer 1950;3:32-35.
22. Wada T, Yokoyama H, Furuichi K, Kobayashi KI, Harada K, Naruto M, Su SB, Akiyama M, Mukaida N, Matsushima K: Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J 1996;10:1418-1425.
23. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, Anders HJ: Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas) lpr mice. J Am Soc Nephrol 2007;18:2350-2358.
24. Tam FW, Sanders JS, George A, Hammad T, Miller C, Dougan T, Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD: Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 2004;19:2761-2768.
25. Rovin BH, Doe N, Tan LC: Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996;27:640-646.
26. Abujam B, Cheekatla S, Aggarwal A: Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. Lupus 2013;22:614-623.
27. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H: Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000;58:1492-1499.
28. Lechner J, Malloth NA, Jennings P, Heckl D, Pfaller W, Seppi T: Opposing roles of EGF in IFN-alpha-induced epithelial barrier destabilization and tissue repair. Am J Physiol Cell Physiol 2007;293:C1843-1850.
29. Tsau Y, Chen C: Urinary epidermal growth factor excretion in children with chronic renal failure. Am J Nephrol 1999;19:400-404.
30. Mathiesen ER, Nexo E, Hommel E, Parving HH: Reduced urinary excretion of epidermal growth factor in incipient and overt diabetic nephropathy. Diabet Med 1989;6:121-126.
31. Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PX, Mariani LH, Eichinger FH, Berthier CC, Randolph A, Lai JY, Zhou Y, Hawkins JJ, Bitzer M, Sampson MG, Thier M, Solier C, Duran-Pacheco GC, Duchateau-Nguyen G, Essioux L, Schott B, Formentini I, Magnone MC, Bobadilla M, Cohen CD, Bagnasco SM, Barisoni L, Lv J, Zhang H, Wang HY, Brosius FC, Gadegbeku CA, Kretzler M, Ercb CPN, Consortium PK-I: Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 2015;7:316ra193.
32. Safirstein R, Zelent AZ, Price PM: Reduced renal prepro-epidermal growth factor mRNA and decreased EGF excretion in ARF. Kidney Int 1989;36:810-815.
33. Humes HD, Cieslinski DA, Coimbra TM, Messana JM, Galvao C: Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 1989;84:1757-1761.
34. Kennedy WA, Buttyan R, Garcia-Montes E, D'Agati V, Olsson CA, Sawczuk IS: Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction. Urology 1997;49:973-980.
35. Lucarelli G, Ditonno P, Bettocchi C, Grandaliano G, Gesualdo L, Selvaggi FP, Battaglia M: Delayed relief of ureteral obstruction is implicated in the long-term development of renal damage and arterial hypertension in patients with unilateral ureteral injury. J Urol 2013;189:960-965.